What is the English name of Acalatinib/Acalatinib?

Acalabrutinib/The English name of Acalabrutinib is Acalabrutinib. This is a small molecule drug that has shown therapeutic efficacy in the treatment of lymphoma. As a second-generation selective inhibitor of Bruton's tyrosine kinase (BTK), acotinib works by blocking a protein called Bruton's tyrosine kinase (BTK) and plays an important role in the treatment of lymphoma.

BTK inhibition in B cells helps block growth and survival signals, leading to B cell death. Acotinib covalently binds to BTK and inhibits its activity, thereby blocking the BCR signaling pathway and further inhibiting the growth and survival of malignant B-cell tumors. This unique mechanism of action makes acotinib show strong potential in the treatment of lymphoma. During the development process, acotinib has undergone rigorous clinical trial verification, proving its safety and effectiveness in the treatment of mantle cell lymphoma (MCL) and other lymphoma types. Due to its excellent efficacy and low side effects, acotinib has become one of the important drugs in the field of lymphoma treatment.

The launch of acotinib provides patients with new treatment options. In China, acotinib was approved for marketing by the State Food and Drug Administration for the first time in May 2023, and has been included in the scope of medical insurance reimbursement. This initiative will greatly reduce the financial burden on patients and improve treatment accessibility for patients.

In addition to mantle cell lymphoma, acotinib has shown promise in the treatment of other types of lymphoma. For example, acotinib has also shown good efficacy and safety in the treatment of chronic lymphocytic leukemia (CLL). In addition, acotinib is also being studied in trials for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), myelofibrosis, ovarian cancer, multiple myeloma and Hodgkin lymphoma, with a view to further expanding its application scope.